Abstract

The invention relates to nucleic acids encoding dominant negative polypeptides comprising the a3 helix of CC2 region and the SUN domain of a SUN domain-containing protein that inhibit the LING complex. The specific embodiment relates to polypeptides of varying lengths derived from amino acids 404-812 of SUN1 with a KDEL signal sequence. It also relates to methods of identifying a LING complex inhibitor and the use of said polypeptides for treating and preventing laminopathies, and diseases characterised by hyperlipidaemia.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61P 3/06 - Antihyperlipidemics

Abstract

Discloses herein is an activated metal-organic framework of formula I as defined in the application, and the metal organic framework has a BET surface area of from 250 to 1,000 m2/g as obtained from a 298 K CO2 sorption isotherm. In a particular embodiment, the activated metal-organic framework is aluminium formate (AI(HCOO)3) or vanadium formate (V(HCOO)3).

IPC Classes  ?

• B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• C01B 32/50 - Carbon dioxide
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C01B 13/02 - Preparation of oxygen
• C01F 7/00 - Compounds of aluminium

Abstract

The invention relates to anti-CEACAM5/6 antigen-binding molecules and humanized variants thereof that bind to CEACAM5/6 that is glycosylated at N256. It also relates to the use of said antigen-binding molecules in methods of detection and medical treatment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/08 - Antiallergic agents

Abstract

Multi-well plate compatible device or insert for three-dimensional (3D) cell cultures, use and kit thereof are provided. The device includes outer and inner walls, the inner wall defining a volume and is located within the outer wall, forming a cavity therebetween. It also includes a base configured to position a cell culture sample below the volume within the inner wall and one or more partitions connected to the base, connecting the inner wall to the outer wall and segmenting the cavity into a plurality of voids. Openings in surfaces forming the voids allow fluid flow from a first void, below the volume within the inner wall to a second void, the fluid flow configured to interact with the cell culture sample when flowing through a sample region within the inner wall. The sample region has a depth defined by a height of the inner wall greater than a length defined by an inner distance across the volume within the inner wall.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to an unbiased and simultaneous amplification method for preparing a double-stranded DNA library from a sample of more than one type of nucleic acid. The method includes providing single-stranded and/or double-stranded DNA and/or RNA as a template; preparing a first DNA strand by annealing to the template a first DNA strand generation primer including (I) a first adaptor sequence followed by a poly-thymidine sequence, a random nucleotide V, and a random nucleotide N and (II) the first adaptor sequence followed by six random nucleotides jointly or independently selected from B, D, H, or V; preparing a second DNA strand by annealing to the first DNA strand a second DNA strand generation primer comprising a second adaptor sequence followed by eight repeating random nucleotides jointly or independently selected from B, D, H, or V, and extending therefrom; and amplifying the second DNA strand via a polymerase chain reaction.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Disclosed herein are methods and treatments for cartilage degradation, wherein the method comprises administration of a therapeutic agent which inhibits the GalNAc-T activation (GALA) pathway.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of treating and preventing diseases associated with fibrosis are disclosed, as well as agents for use in such methods. The methods comprise inhibiting at least one of ITFG1, MFAP4, GRHPR, ABCC4, PAK3, TRNP1, APLN, KIF20A, and/or LTB. In one embodiment, the disease is a liver disease or condition. Also disclosed are methods of promoting regeneration of cells, such as hepatocytes.

IPC Classes  ?

• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a pair of non-naturally occurring nucleic acid probes for detecting a polynucleotide analyte for fluorescence in situ hybridization (FISH) wherein the probes comprise a first nucleic acid probe comprising a first probe binding arm that is complementary to a first probe target region of a bridge probe and a first polynucleotide analyte binding arm that is complementary to a first analyte target region of a polynucleotide analyte and a second nucleic acid probe comprising a second probe binding arm that is complementary to a second probe target region of the bridge probe. The binding of the pair of probes to target polynucleotides permits the binding of the bridge probe to allow detection of the polynucleotide analyte. It also provides a probe system comprising said pair of nucleic acid probes and methods of detecting polynucleotide analytes in a sample.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6841 - In situ hybridisation

Abstract

The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• G01N 33/577 - Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies

Abstract

The invention concerns a compound of formula (Ia) or (Ib) wherein R1 is hydrogen or a methyl group; R2 is an unsubstituted or substituted alkyl group; R3 is an aryl group or a heteroaryl group, optionally substituted by one or more groups selected from halogen, alkyl or alkoxy; and, in Formula (Ia), X is CH or N and Y is NH, S or O, or, in Formula (Ib), X is NH, S or O and Y is CH or N. The invention further concerns a method of synthesizing the inventive compound, a composition comprising the inventive compound or a pharmaceutically acceptable salt thereof and bedaquiline (BDQ), an analogue of bedaquiline (BDQ) or a mixture thereof, and the use of said composition or compound for the treatment of tuberculosis.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1 A and GLRX3 correspond to unhealthy.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Methods for the treatment and prevention of laminopathies and diseases characterised by hyperlipidemia through LING complex inhibition are disclosed. In particular, LING complex disruption by expression of dominant-negative LING complex proteins alleviates pathophysiology in Lmna mutation-associated muscular dystrophy, progeria, and dilated cardiomyopathy. In addition, LING complex disruption by expression of dominant-negative LING complex proteins also alleviates pathophysiology in mouse models of atherosclerosis and familial hypercholesterolemia.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/861 - Adenoviral vectors

Abstract

The present invention provides methods for enriching a target complementary DNA (cDNA), comprising: (a) providing a plurality of cDNAs, each comprising a first universal sequence at an end, and wherein the plurality of cDNAs comprises the target cDNA; (b) amplifying the target cDNA with a universal forward primer complementary to the first universal sequence and a gene specific reverse primer, and wherein a second universal sequence is added to an end of the cDNA opposite the first universal sequence, by a nucleic acid amplification reaction, by ligation, or by a primer extension reaction; and (c) amplifying the amplicons or extension products using the universal forward primer and a universal reverse primer complementary to the second universal sequence. In one embodiment, the universal forward primer, the gene specific reverse primer and the second universal reverse primer are provided in the same reaction mixture such that the amplifying is a single step.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6869 - Methods for sequencing

Abstract

The disclosure provides anti-dengue virus (anti-DENV) antibodies having a cross-reactivity to Zika virus (ZIKV) and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection. In addition, claimed antibodies may further comprise variant Fc regions containing LALA, KAES & ACT5 mutations.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61P 31/12 - Antivirals

Abstract

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and/or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/861 - Adenoviral vectors

Abstract

Here are described core shell nanoparticles comprising a porous metal oxide core of formula MyOx, a shell layer comprising TiO2 and elemental sulfur (S8), as an electrochemically active material, incorporated into the pores of the porous metal oxide core, their use in electrode materials as well as their methods of preparation. In a preferred embodiment, the porous metal oxide core is manganese oxide (MnO) and the elemental sulfur is incorporated into the pores of the porous metal oxide core through a melt diffusion process. Also described are composite materials, electrode materials, electrodes, and electrochemical cells comprising the core shell nanoparticles and their use in lithium sulfur batteries.

IPC Classes  ?

• H01M 4/50 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese
• H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulators; Processes of manufacture thereof
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention provides methods, antibodies and kits for detecting and/or quantifying expression of both non- nucleic acid molecules, such as proteins, and nucleic acid molecules in a single sample or single cell. The antibody is covalently conjugated to an oligonucleotide, such as a single-stranded DNA molecule, which comprises an identification tag and a blocking group, such as a ddNTP or an inverted dTTP, which prevents extension of the oligonucleotide by a polymerase. The method comprises the steps of reverse transcribing the conjugated oligonucleotide and the target nucleic acid simultaneously, amplifying both transcription production, and detecting the amplicons thereof. The method is also useful for detecting and/or quantifying the number of cells in a sample expressing a given non -nucleic acid molecule (e.g. protein).

IPC Classes  ?

• C12Q 1/6804 - Nucleic acid analysis using immunogens
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

IPC Classes  ?

• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 211/24 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by sulfur atoms to which a second hetero atom is attached

Abstract

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti- DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61P 31/12 - Antivirals

Abstract

The present invention relates to humanised antibodies that bind phosphatase of regenerating liver-3 (PRL3) and use of said antibodies for the treatment of cancer. Also claimed is an in vitro method of determining the cellular localisation of PRL3 in a cell, wherein expression of PRL3 at the cell surface indicates that the cell is cancerous.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/46 - Hybrid immunoglobulins

Abstract

A column-based device and method for retrieving cells of interest were enclosed. The said device comprises a column comprising (i) an inner wall defining an inner chamber with inlet and outlet openings, (ii) a perforated plug disposed adjacent to the outlet opening, (iii) a sleeve insert with a channel and disposed within the chamber and adjacent to the perforated plug, and (iv) a filtering means housed within sleeve insert sandwiched between two sealing means. In particular, Tumor-derived endothelial cell clusters (TECCs) as characterized multiple nuclei, expression of endothelial markers (PECAM1, VWF and CDH5), and non-expression of leukocyte, megakaryocyte and platelets markers, may be retrieved using the disclosed device. Also encompassed are methods, reagents and kits for the diagnosis and prognosis of cancers by detecting for the presence of TECCs isolated from blood samples using the claimed device.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• G01N 1/34 - Purifying; Cleaning
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/537 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 37/02 - Immunomodulators

Abstract

The present relates to a water-soluble pouch comprising a water soluble film encapsulating a composition, wherein the film comprises at least one area of embossment.

IPC Classes  ?

• C11D 17/08 - Detergent materials or soaps characterised by their shape or physical properties capsuled
• C08J 5/12 - Bonding of a preformed macromolecular material to the same or other solid material such as metal, glass, leather, e.g. using adhesives
• C08L 101/14 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity the macromolecular compounds being water soluble or water swellable, e.g. aqueous gels

Abstract

The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.

IPC Classes  ?

• C07D 473/08 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/06 - Antipsoriatics
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 473/06 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Abstract

A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells whilst maintaining their pluripotency/multipotency.

IPC Classes  ?

• C08B 37/10 - Heparin; Derivatives thereof
• A61K 31/727 - Heparin; Heparan
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

A method and apparatus for detecting underwater sounds is disclosed. An embodiment of the apparatus includes a substrate with a vacuum-sealed cavity. A support structure and an acoustic pressure sensor are situated on the substrate. The support structure of the apparatus may include a first oxide layer situated on the substrate, a silicon layer situated on the first oxide layer, and a second oxide layer situated on the silicon layer. The acoustic pressure sensor of the apparatus includes a first electrode layer situated on the substrate, a piezoelectric layer situated on the first electrode layer, and a second electrode layer situated on the piezoelectric layer. In one embodiment, the surface area of the second electrode layer is between about 70 to 90 percent of the surface area of the piezoelectric layer. In various embodiments, the support structure is thicker than the piezoelectric layer.

IPC Classes  ?

• G01H 3/10 - Amplitude; Power
• G01H 11/08 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by detecting changes in electric or magnetic properties by electric means using piezoelectric devices
• G01V 1/18 - Receiving elements, e.g. seismometer, geophone

Abstract

A method and system for concentration detection. The method for concentration detection comprises the steps of extracting temporal features from brain signals; classifying the extracted temporal features using a classifier to give a score x1; extracting spectral-spatial features from brain signals; selecting spectral- spatial features containing discriminative information between concentration and non-concentration states from the set of extracted spectral-spatial features; classifying the selected spectral-spatial features using a classifier to give a score x2; combining the scores x1 and x2 to give a single score and determining if the subject is in a concentration state based on the single score.

IPC Classes  ?

• G06F 17/16 - Matrix or vector computation
• G06F 17/18 - Complex mathematical operations for evaluating statistical data